Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health Insights GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs (NASDAQ:AIDX), an early market leader in cutting-edge, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announces the launch and commercial availability of its OneTest for Longevity solution. The solution uses IBM watsonx.ai – an integrated AI application development studio – to analyze data, to help individuals track chronic inflammation associated with several major chronic diseases. T

GAITHERSBURG, Md., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX), an early market leader in cutting-edge, AI-powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced today that it will hold a virtual investor webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time. 20/20 BioLabs President and CEO Jonathan Cohen will host the webinar to discuss the company's recent Nasdaq listing, OneTest™ for Cancer™ AI powered multi-cancer early detection ("MCED") blood test, One Test for Longevity™ expected to be launched before the end February, ongoing initiatives, and upcoming milestones. A question-and

4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)